…but a chemically-altered analog derived from feverfew appears to have anticancer activity against leukemia stem cells. Researchers at the University of Rochester reported this week in the journal, Blood, that dimethylaminoparthenolide (DMAPT) has selective action against acute myeloid leukemia (AML).
It’ll be a couple days before I can get to reading the original paper. However, do not let anyone tell you that feverfew can treat cancer. From the press release, it appears that the major compound in feverfew, called parthenolide, was chemically modified to create DMAPT, thereby converting parthenolide into a form that gets absorbed into the bloodstream and has a reasonable half-life once it’s there.
To be clear, DMAPT is not present in feverfew. It is a feverfew component modified in the laboratory in a manner that cannot be accomplished by the body.
I say this emphatically because I’ve already seen sites popping up on the Web advertising their feverfew products as “high in parthenolide” and then having a description of the Rochester paper (no, I’m not giving links to this absurdity).
More to follow but, please, be vigilant and don’t be misled.